Although regular or prophylactic administration of G‐CSF to treat neutropenia was not performed in this trial, it is crucial to consider the timing of G‐CSF or PLAG administration in adjuvant chemotherapy to prevent associated neutropenia. The gene discussed is CSF3; the disease is neutropenia.